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Abstract
Human respiratory syncytial virus (HRSV) has a single-stranded, negative-sense RNA genome with 10 genes encoding 11 proteins.
Sequences at the beginning of the HRSV genes are highly conserved; however, the gene end sequences vary around a semiconserved
consensus sequence, and the nontranscribed intergenic regions vary in both length and sequence. The regions at the junctions between HRSV
genes (the gene end sequence of an upstream gene, intergenic region, and the gene start sequence of a downstream gene) contain elements
required for efficient termination of the upstream gene and transcription of the downstream gene. Previous studies have examined variation
in the HRSV coding sequences, but none have systematically analyzed the noncoding transcriptional control regions for variability. We
determined the gene start and gene end sequences of each of the 10 HRSV genes from 14 clinical isolates for variations from the sequence
of the prototype A2 strain. No changes were found in any of the gene start sequences. Eight of the 10 gene end sequences, however,
contained variations. Several of these, a U4-tract instead of a U6- or U5-tract at the M and SH gene ends, respectively, (U4A) and an A-to-G
change at position four in the G gene end (A4G), were predicted to affect termination and were examined for their effects on transcription.
The changes were found to inhibit transcriptional termination, resulting in increased polycistronic readthrough and correspondingly reduced
initiation of the downstream monocistronic mRNA. Viruses with the A4G variant G gene end sequence produced less F protein than those
with A2-like G gene end sequences. Examination of additional G gene end sequences available in GenBank revealed that the observed A4G
variation was restricted to one phylogenetic lineage of HRSV. All viruses examined within this lineage possessed this variant G gene end
sequence. The data presented show that the gene end sequences of naturally occurring HRSV clinical isolates vary from those of the
prototypic A2 strain and that certain of these changes inhibit efficient transcriptional termination and downstream gene expression.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Human respiratory syncytial virus (HRSV), a member of
the Paramyxoviridae family, is the leading cause of viral
pediatric pneumonia and bronchiolitis (Collins et al., 2001;
Hall, 1999). HRSV has a monopartite, negative-sense RNA
genome containing 10 genes that encode 11 known viral
proteins (Collins et al., 1984; Collins and Wertz, 1983).
Transcription of the HRSV genome proceeds from a single
3 promoter and is obligatorily sequential, such that termi-
nation of each upstream gene is required for transcription of
the downstream gene (Collins et al., 1984, 2001; Collins and
Wertz, 1983). In addition, there is transcriptional attenua-
tion at each gene junction, such that viral gene expression is
primarily controlled by the position of a gene relative to the
3 end of the genome (Collins et al., 2001; Dickens et al.,
1984; Pringle and Easton, 1997).
Because the HRSV genome has a single 3 transcriptional
promoter, the polymerase must transcribe and terminate
each successive gene to initiate transcription of the gene
immediately downstream (Collins et al., 2001; Dickens et
al., 1984; Pringle and Easton, 1997). Each HRSV gene
contains a highly conserved sequence at its beginning and a
partially conserved sequence at its end, as shown in Table 1.
The nontranscribed sequences between the end of an up-
stream gene and the beginning of a downstream gene, called
the intergenic regions, vary in both length and sequence
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(Collins et al., 1986). Collectively, the region containing the
gene end sequence of the upstream gene, the intergenic
region, and the gene start sequence of the downstream gene
are termed the gene junction. This region contains elements
required for termination of the upstream gene and transcrip-
tion of the downstream gene. Sequences at the start of each
gene (3 . . .CCCc/uGUUUa/uA. . . 5) are required for ini-
tiation of transcription (Kuo et al., 1996, 1997). The semi-
conserved gene end sequences (3 . . .UCAAUN1–4U4–7. . . 5)
and the first nucleotide of the nonconserved intergenic re-
gion contain signals required for efficient termination and
polyadenylation of the viral mRNAs (Barr et al., 1997;
Harmon et al., 2001; Hwang et al., 1998; Kuo et al., 1996,
1997). Termination efficiencies at the HRSV gene junctions
vary, with the NS1/NS2 gene junction being the least effi-
cient and the SH/G junction being the most efficient when
each authentic junction was analyzed using dicistronic sub-
genomic replicons (Cartee et al., 2003; Hardy et al., 1999).
Previous work has characterized the nucleotide se-
quences required for efficient termination at an HRSV gene
end (Cartee et al., 2003; Harmon et al., 2001; Harmon and
Wertz, 2002; Sutherland et al., 2001). In work using a
dicistronic subgenomic replicon system containing the
M/SH gene junction, individual point mutations to all pos-
sible nucleotides and/or deletions were made at each posi-
tion of the M gene end sequence. Each region within the
gene end sequence, the conserved 3 . . .UCAAU. . . 5
region, the nonconserved central region, and the U-tract,
was found to be required for termination (Cartee et al.,
2003; Harmon et al., 2001). Certain positions of the 3. . .
UCAAU. . . 5 region and central region had specific se-
quence requirements for efficient termination (positions 2
through 5 in the UCAAU and positions 6 and 8 in the
central region); the length and position of the U-tract were
also shown to be critical (Cartee et al., submitted for pub-
lication; Harmon et al., 2001; Harmon and Wertz, 2002). In
general, the 3. . . UCAAU. . . 5 was most sensitive to
single base changes, with some changes resulting in de-
creases in termination efficiency of up to 90%. In subse-
quent work, an A at the position immediately upstream of
the 3 . . .UCAAU. . . 5, referred to as the1 position, also
was shown to be important for efficient termination (Har-
mon and Wertz, 2002). Separate studies examining certain
single nucleotide changes made at the F gene end found
similar results (Sutherland et al., 2001). Together, these
studies provide an overall framework for defining the gene
end sequences involved in transcriptional termination.
HRSV subgroup A clinical isolates are distributed into
two main evolutionary lineages based on phylogenetic anal-
yses of their G gene sequences (Choi and Lee, 2000; Cog-
gins et al., 1998; Peret et al., 2000; Sullender, 2000). The
prototype strains, A2 and Long, cluster in one of these
lineages, along with isolates in the genotype GA1 (Sul-
lender, 2000); the second lineage contains genotypes GA2–
GA7 (Peret et al., 2000). Previous work examining variation
in the coding regions of several HRSV genes found that the
coding regions of the genes were variable, but not equally so
(Cane et al., 1991; 1994; Choi and Lee, 2000; Coggins et al.,
1998; Garcia et al., 1994; Melero et al., 1997; Peret et al.,
2000; Sullender, 2000; Waris, 1991). The G gene was
highly variable, both between subgroups A and B (approx-
imately 50% variation) and within subgroup A (up to 20%
variation). The SH gene was the next most variable, while
genes such as N had little variation. In most of these studies,
only the coding regions were examined; none examined
variation of regions known to be involved in transcriptional
regulation, such as the gene end and gene start sequences.
In this study, we determined the sequences at the begin-
ning and end of each of the 10 HRSV genes of 14 subgroup
A isolates from the USA and UK and analyzed these se-
quences along with available sequences from GenBank. The
gene start sequences were absolutely conserved among all
isolates examined. However, at 8 of the 10 gene ends we found
variations in the nucleotides within the generally defined
HRSV gene end consensus sequence (3 . . .UCAAUN1–4U4–
7. . . 5). The effect of these changes on transcriptional termi-
nation was examined.
Results
Analysis of gene start and gene end sequences of HRSV
clinical isolates
We determined the gene start and gene end sequences of
the 10 HRSV genes from six clinical isolates from Alabama,
USA and eight clinical isolates from Glasgow, Birmingham,
and Newcastle, UK. Twelve of the isolates represented four
genotypes (GA1: RSB89-1734, AL-194465, AL-195131;
GA2: RSB89-8106; GA3: RSB89-5857, RSB89-6256,
RSB89-6614, AL-205342; GA5: RSB89-6190, AL-180081,
AL-180893, AL-203721), while two isolates did not fall
into any defined genotype (RSG1503: similar to GA1;
Table 1
HRSV gene junction sequences (A2 strain)a
Gene Gene end IG Gene start
1 1 5 9 13
NS1/NS2 a UCAAUuauaUUUU (19) CCCCGUUUA
NS2/N a UCAuUaaa-UUUU (26) CCCCGUUUA
N/P c UCAAUuauuUUUU (1) CCCCGUUUA
P/M a UCAAUguuuUUUU (9) CCCCGUUUA
M/SH u UCAAUuauuUUUU (9) CCCCGUUUA
SH/G a UCAAUuaauUUUU (44) CCCCGUUUA
G/F a UCAAUgaauUUUU (52) CCCCGUUUA
F/M2 a UCAAUaua-UUUU (46) CCCCGUUUA
Gene L gene start Overlap M2 gene end
M2/L aCCCugUUUua (64) UCAAUaaa-UUUU
a Genomic RNA sequences of the gene ends and gene starts are shown
in 3 to 5 orientation. Conserved nucleotides are in uppercase and the
U-tract is underlined. IG: intergenic region.
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RSS2: similar to GA5) (Cane et al., 1994; Cane and Pringle,
1995; Coggins et al., 1998; Peret et al., 2000; Sullender,
2000; Tolley et al., 1996).
No sequence variation from the prototype HRSV se-
quence (A2, isolated in Melbourne, Australia in 1961) was
found at any of the clinical isolates’ gene starts (data not
shown). However, variation was found in 8 of the 10 gene
end sequences, shown in comparison to the sequence at each
gene end of the prototype A2 strain (Table 2). No variation
from the A2 sequence was found at the ends of the NS2 and
M2 genes. The NS1, N, P, SH, and F gene ends all had
sequences identical to the A2 strain in the conserved
3 . . .UCAAU. . . 5, in the central region, and at the
1 position, but had variations in their U-tract lengths
(Table 2). These variations ranged from single uridine de-
letions (N, P, and SH) to single (N, SH, and F), double (F),
or triple (NS1) uridine insertions. The M and L gene ends
had variations in both central region length and U-tract
length (Table 2). All of these variations were within the
generally defined HRSV consensus gene end sequence
(3 . . .UCAAU-N1–4-U4–7. . . 5) derived from the gene end
sequences of the A2 strain (Collins et al., 2001).
At the G gene end, variations were found in all three
regions within the gene end sequence, with only 2 of the 14
isolates containing the A2-like sequence (Table 2). One
variation, a single uridine insertion in the U-tract, was found
in two isolates. Another variation, found in 12 isolates, was
a single nucleotide deletion in the nonconserved central
region of the gene end sequence at position 6, as defined in
Table 1, henceforth called -6G. These variations were
within the previously described general consensus gene end
sequence and, for the purposes of this study, are considered
to be A2-like sequences. However, among the 12 isolates
with the -6G variation, 10 contained a second variation, an
A-to-G change at position 4 in the gene end sequence,
henceforth called A4G. This variation was not found at any
other gene end and was not within the general HRSV gene
end consensus sequence.
When the isolates’ G gene end sequences were compared
to their positions in a phylogenetic tree (Coggins et al., 1998),
it was found that the isolates within the lineage containing
the A2 and Long strains all had an A2-like G gene end
sequence, while isolates belonging to the other subgroup A
lineage all had the A4G variant G gene end sequence. We
then examined G gene end sequences from GenBank for
which phylogenetic data was available to determine if these
grouping patterns were widespread (Cane et al., 1991, 1994;
Coggins et al., 1998; Garcia et al., 1994; Peret et al., 2000;
Roca et al., 2001). Analysis of these sequences showed that
the A4G variation was found only in isolates in the second,
non-A2 lineage (Fig. 1). Moreover, all isolates in this lin-
eage for which G gene end sequences were available con-
tained the A4G variant G gene end sequence.
Of the nucleotide variations observed in the 14 isolates
we sequenced, changes at three of the gene end sequences
would be predicted to affect termination, based on previous
analyses (Cartee et al., 2003; Harmon et al., 2001; Harmon
and Wertz, 2002; Sutherland et al., 2001). A U4-tract was
previously shown to decrease termination when combined
with an intergenic region beginning with an A (Cartee et al.,
2003; Harmon and Wertz, 2002; Sutherland et al., 2001);
this change was found at the M gene end of one isolate and
the SH gene end of four isolates. A change at position 4 of
the 3 . . .UCAAU. . . 5 sequence, found at the G gene end
of 62 isolates, severely inhibited termination when exam-
ined at the M gene end in a subgenomic replicon (Cartee et
al., 2003; Harmon et al., 2001). The effects of these two
types of changes were examined in the context of their
natural gene junction sequences, as described below.
Effect on termination of a shortened U-tract at the SH
gene end
It has been shown previously that a gene end with a
U-tract of four nucleotides in combination with an inter-
Table 2
Clinical isolate gene end sequences
Gene Gene end sequencesa Number of
isolatesb
Isolate sequences
from GenBank
NS1 UCAAUUAUAUUUU (A2) 13 N/A
UCAAUUAUAUUUUUUU 1
NS2 UCAUUAAAUUUU (A2) 14 N/A
N UCAAUUAUUUUUU (A2) 5 N/A
UCAAUUAUUUUU- 4
UCAAUUAUUUUUUU 5
P UCAAUGUUUUUUU (A2) 13 N/A
UCAAUGUUUUUU- 1 N/A
M UCAAUUAUUUUUU (A2) 0 N/A
UCAAUUAUUUUU- 13
UCAAUUAAUUUU- 1
SH UCAAUUAAUUUUU (A2) 7 N/A
UCAAUUAAUUUU- 4
UCAAUUAAUUUUUU 3
G UCAAUGAAUUUUU (A2) 2 0
UCAAU-AAUuuuu 0 12
UCAAU-AAUUUUUU 2 0
UCAAU-AAUUCUUUU 0 1
UCAGU-AAUuuuu 10 53
UCAGUAAAuuuuu 0 5
F UCAAUAUAUUUU (A2) 11 N/A
UCAAUAUAUUUUU 1
UCAAUAUAUUUUUU 2
M2 UCAAUAAAUUUU (A2) 14 N/A
L UCAAUAAUUUUU (A2) 3 N/A
UCAAUAAUUUUUU 1
UCAAUAAAUUUU 10
a Genomic RNA sequences are shown in 3 to 5 orientation, beginning
at position 1. Changes from the A2 sequence are shown in bold. Sequences
in which U-tract information is available for only some of the isolates
included in the total are shown in lowercase. N/A: not available.
b Includes only isolates sequenced in this study.
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genic region beginning with an A inhibits efficient tran-
scriptional termination at the M/SH and F/M2 gene junc-
tions (Cartee et al., 2003; Harmon and Wertz, 2002;
Sutherland et al., 2001). The A2 sequence at the M/SH and
SH/G gene junctions includes a U-tract of six and five
nucleotides, respectively, coupled with an intergenic region
beginning with an A. One clinical isolate contained a dele-
tion of two nucleotides in the U-tract of its M gene end
(Table 2). This deletion was previously examined in the
context of an M/SH subgenomic replicon and was found to
significantly decrease termination (Cartee et al., 2003; Har-
mon et al., 2001; Harmon and Wertz, 2002).
Four clinical isolates were found to contain a single
nucleotide deletion in their SH gene end U-tracts (Table 2)
that, based on previous mutagenic analysis, would be pre-
dicted to decrease termination efficiency at the SH/G gene
junction in these isolates (Cartee et al., 2003; Harmon et al.,
2001; Harmon and Wertz, 2002; Sutherland et al., 2001). To
examine the effect of this U-tract variation on termination at
this gene junction, we deleted a single uridine from the
U-tract of the SH gene end in a dicistronic subgenomic
replicon, pSH/G, which had previously been characterized
(Hardy et al., 1999). A schematic of these replicons is
shown in Fig. 2A. RNA synthesis directed by replicons
containing either A2 or variant SH gene ends was assayed in
HEp-2 cells infected with MVA-T7, a recombinant vaccinia
virus that expresses T7 RNA polymerase, and then cotrans-
fected with a plasmid expressing one of the subgenomic
replicons and plasmids encoding the N, P, L, and M2-1
proteins. RNA species produced from the replicons were
metabolically labeled with [3H]uridine in the presence of
actinomycin D and cytosine arabinoside to inhibit DNA-
dependent RNA synthesis. Following electrophoretic sepa-
ration of RNA products on agarose-urea gels and fluorog-
raphy, termination at the A2 and variant SH/G gene
junctions was analyzed as described under Materials and
methods, by determining the level of a readthrough product
resulting from the failure to terminate at the SH gene end
sequence.
Although the overall level of readthrough RNA species
synthesized was very low, readthrough synthesis at the
SH/G gene junction was consistently increased in the vari-
ant replicon pSH/G-4U (2.5  0.07%) as compared to
replicon pSH/G (0.4  0.07%) (Fig. 2B). These data con-
firm the previous finding that a U-tract of four nucleotides in
combination with an intergenic region beginning with an A
signals transcriptional termination with reduced efficiency
(Cartee et al., 2003; Harmon and Wertz, 2002; Sutherland et
al., 2001).
Effect of G gene end sequence variations on
transcriptional termination and downstream gene
expression
Nearly all clinical isolates examined had changes in at
least one region within their G gene end sequences (Table
2). Of these, the change at position 4 in the gene end signal
(3 . . .UCAAU. . . 5) had the greatest potential to affect
transcriptional termination, based on previous work which
showed that if this A was changed to any other nucleotide,
transcriptional termination was significantly decreased
(Cartee et al., 2003; Harmon et al., 2001). Changes in the
length of the central region of the gene end sequence also
decreased termination efficiency, while increasing the
length of the U-tract had little effect on transcription.
Whereas the previous work was done in the context of the
Fig. 1. Phylogenetic analysis of G protein sequences from HRSV clinical
isolates. Isolates are identified according to their geographic location of
isolation (al: Alabama, USA (Coggins et al., 1998); uk: United Kingdom
(Cane et al., 1991); mad: Madrid, Spain (Garcia et al., 1994); mon:
Montevideo, Uruguay (Garcia et al., 1994); aus: Australia (Wertz et al.,
1985)), isolate number, and for the Madrid and Montevideo isolates, year
of isolation. Isolates whose gene starts and gene ends were sequenced in
this study are shown in bold, and the lineages containing the A4G variation
and the A2 prototype strain are labeled (adapted from Coggins et al., 1998,
reproduced by permission of the American Society for Microbiology).
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M/SH gene junction, we examined the effect of the A4G
and -6G variations in their natural context, the G/F gene
junction. A dicistronic, subgenomic replicon pG/F, which
contained the G/F gene junction surrounded by 216 nucle-
otides of the upstream G gene and 356 nucleotides of the
downstream F gene from the A2 strain of HRSV (nucleo-
tides 5367 to 6013), was characterized previously (Hardy et
al., 1999). We introduced the A4G or -6G variations into the
consensus A2 background of pG/F by site-specific mutagen-
esis (Fig. 3A). The effect of these variations was then
examined by transfection of the replicons into HEp-2 cells
and metabolic labeling of RNA products with [3H]uridine in
the presence of actinomycin D, as described above.
When compared to the A2 G/F replicon (pG/F), both
replicons containing the A4G variation, either alone (pG/F-
A4G) or in combination with the -6G variation (pG/F-A4G
-6G), synthesized lower levels of the monocistronic RNA
species mRNA1 and mRNA2 and higher levels of a
readthrough product resulting from the failure to terminate
Fig. 3. Effect of the A4G and -6G variations on termination at the G gene
end. (A) Schematic of pG/F and variant dicistronic replicons. Each replicon
contains 625 nucleotides surrounding and including the HRSV G/F gene
junction from the A2 strain. The A4G and -6G variations were introduced
into pG/F individually and in combination. (B) Readthrough and down-
stream mRNA synthesis of pG/F, pG/F-A4G(-6G), pG/F-A4G, and pG/F-
(-6G). RNA species were analyzed as for Fig. 2B. Readthrough and
downstream mRNA synthesis were determined as described under Mate-
rials and methods.
Fig. 2. Effect of a single nucleotide deletion in the SH gene end U-tract on
termination. (A) Schematic of pSH/G and pSH/G-4U dicistronic replicons.
Each replicon contains 678 nucleotides surrounding and including the
HRSV SH/G gene junction from the A2 strain. pSH/G-4U has a single
nucleotide deletion in the U-tract of the SH gene end. The relevant RNA
species produced from these replicons are shown: (1) genomic replication
product (rep.); (2) upstream mRNA product (mRNA 1); (3) downstream
mRNA product (mRNA 2); and (4) upstream–downstream readthrough
product (r/t 1–2). le: leader region; tr: trailer region. (B) Readthrough
synthesis by pSH/G and pSH/G-4U. HEp-2 cells were infected with
MVA-T7 and then transfected with plasmids expressing HRSV N, P, M2,
and L proteins and a plasmid encoding the replicon, all with T7 promoters.
RNA products synthesized from the replicon templates were metabolically
labeled with [3H]uridine in the presence of actinomycin D, separated by
electrophoresis on agarose-urea gels, and visualized by fluorography. Rep-
lication and transcription products are indicated. Readthrough synthesis
was determined as described under Materials and methods.
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at the G gene end sequences (Fig. 3B). Readthrough syn-
thesis at the G gene end sequence of pG/F-A4G (36 
2.2%, Fig. 3B, lane 2) was approximately 10-fold higher
than that of pG/F (4  0.2%, Fig. 3B, lane 1). Correspond-
ingly, the relative amount of mRNA2 was also decreased,
consistent with the sequential nature of HRSV transcription,
in which termination at the upstream gene end is required
for initiation at the downstream gene start. When both
variations were present in the G gene end sequence, as in
pG/F-A4G(-6G), the increase in readthrough synthesis was
only four-fold relative to pG/F (16 3.0%, Fig. 3B, lane 4).
Readthrough synthesis at the G gene end of pG/F-(-6G) (3
 0.6%, Fig. 3B, lane 3), which contained only the -6G
variation, was essentially unchanged relative to pG/F. These
results confirmed the previous finding (Cartee et al., 2003;
Harmon et al., 2001) that changing the A at position 4 of the
conserved 3 . . .UCAAU. . . 5 region of the gene end
sequence decreased termination and downstream gene ex-
pression. They also demonstrated that while the -6G varia-
tion had little effect on termination when present on its own,
it could partially compensate for the A4G variation when
the two were present together.
Relative amount of F protein produced by clinical isolates
Because HRSV transcription is obligatorily sequential, a
polymerase that fails to terminate at a gene end sequence
produces a dicistronic mRNA, of which only the upstream
gene is likely to be available for translation by the ribosome.
Once this dicistronic product is made, the polymerase does
not go back to transcribe a discrete mRNA from the down-
stream gene. Therefore, decreased termination of an up-
stream gene would result in decreased expression of the
downstream monocistronic mRNA and its gene product. In
the case of the G gene end, decreased termination would be
predicted to lead to decreased expression of the F protein.
We have shown that replicons containing the A4G variant
G/F gene junction produced lower levels of the downstream
message (Fig. 3B, Lanes 2 and 4). However, since all of the
isolates containing the A4G variation also contained the -6G
variation, and in the replicon context this combination in-
creased readthrough (Fig. 3B, Lane 4), but to a lesser extent
than when the A4G variation was present alone (Fig. 3B,
Lane 2), it was possible that this smaller difference in
readthrough would not lead to a measureable difference in F
protein expression. To test whether a virus with an A4G(-
6G) variant G gene end expressed less F protein than one
with an A2-like G gene end, we infected HEp-2 cells with
clinical isolates containing A4G(-6G) variant G gene ends
(AL-180893, AL-180081) or an A2-like G gene end (AL-
195131), or HRSV A2 (Fig. 4A) and labeled proteins with
[35S]methionine and [35S]cysteine in the presence of acti-
nomycin D. 35S-labeled proteins were immunoprecipitated
with polyclonal antisera against HRSV, and quantitation
was performed following reducing SDS–PAGE of the im-
munoprecipitated proteins. Antibody was confirmed to be in
excess by immunoprecipitation with twice the original input
amount of antisera.
To compare the amounts of F protein expressed by the
clinical isolates, we determined their F:N and F:M protein
ratios, which measured the amount of F protein expressed
by an isolate relative to the amount of N protein or M
protein expressed by that isolate. Since both the N and the
M genes precede the G/F gene junction in the HRSV ge-
nome, expression of their gene products should not be
affected by altered termination downstream in the genome.
Comparison of relative amounts of F protein allowed us to
correct for any discrepancies in overall F protein levels that
may occur as a result of different rates of replication of the
viruses. The amounts of M protein relative to N protein
produced by each of the viruses were also compared as an
Fig. 4. F protein production from clinical isolates with A4G variant or
A2-like G gene end sequences. (A) G gene end sequences of clinical
isolates AL-180893, AL-180081, and AL-195131 compared to the A2
strain G gene end sequence. Variations from the A2 G gene end sequence
are shown in bold. (B) Levels of F protein produced by clinical isolates and
A2 relative to N and M proteins. HEp-2 cells were infected with the clinical
isolates AL-180893, AL-180081 (A4G variants), or AL-195131 (A2-like),
or A2 at an m.o.i. of 0.5 in MEM, or mock-infected with MEM, and
incubated for 16 h at 37°C. Proteins were labeled with [35S]methionine/
cysteine in the presence of actinomycin D. Cell lysates were immunopre-
cipitated with polyclonal anti-HRSV antibodies (Chemicon) and the pro-
teins were run on an 11% SDS–PAGE gel. Viral proteins were visualized
and quantitated using a PhosphorImager. The amount of F protein pro-
duced by each isolate was normalized to the amount of N protein (dark
gray) or to the amount of M protein (light gray). Shaded bars represent the
mean of at least two separate experiments, with error bars indicating the
standard deviations.
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internal control. Isolates AL-180893 and AL-180081 (both
with the A4G variation) expressed decreased amounts of F
protein when compared to isolate AL-195131 (A2-like) and
A2 (Fig. 4B), while the amounts of M protein relative to N
protein produced by all of the viruses were similar (data not
shown). Immunoprecipitation with monoclonal antisera
against the HRSV F protein and N protein gave similar
results (data not shown). It is interesting to note that the
magnitude of the decrease in F protein appears similar to
that of the decrease in mRNA2 synthesis seen in Fig. 3B.
While we cannot be certain that the A4G variation is wholly
responsible for the observed phenotype, since these viruses
have many sequence changes in addition to those at the G
gene end, these data show that the isolates containing the
A4G variations at their G gene ends produce less F protein
than viruses containing the A2 sequence at their G gene
ends.
Discussion
The semiconserved gene junctions of HRSV are respon-
sible for directing termination of the upstream message and
initiation of the downstream message. Previous work from
our lab and others has determined the sequence elements
critical for the efficiency of each of these processes, in the
context of subgenomic replicons (Cartee et al., 2003; Har-
mon et al., 2001; Kuo et al., 1997; Sutherland et al., 2001).
It was found that the integrity of each sequence element (the
3 . . .UCAAU. . . 5, the central region, and the U-tract) in
the gene end sequence was critical for efficient transcrip-
tional termination (Cartee et al., 2003; Harmon et al., 2001;
Sutherland et al., 2001).
We determined the gene junction sequences from 14
clinical isolates of HRSV and found that, although there was
no variation in the gene start sequences, the gene end se-
quences varied considerably. The most common variations
found at any gene end were deletions or additions of uri-
dines in the U-tract. Increases in the length of the noncon-
served central region were also found in some gene end
sequences with shorter U-tracts. Although each of these
variations was within the general consensus sequence for an
HRSV gene end (3 . . .UCAAU-N1–4U4–7. . . 5), work
with both HRSV and Simian parainfluenza virus 5 (SV-5)
has shown that there was decreased termination efficiency
when a gene end U-tract of four nucleotides was combined
with an intergenic region beginning with an A residue
(U4A) (Cartee et al., 2003; Harmon and Wertz, 2002; Rassa
and Parks, 1999; Sutherland et al., 2001). The M/SH gene
junction of one isolate and the SH/G gene junction of three
isolates were observed to have the U4A sequence. The effect
of this variation on the M/SH gene junction has been ana-
lyzed previously and was found to inhibit termination (Car-
tee et al., 2003; Harmon and Wertz, 2002). When the effect
of the U4A variant SH gene end sequence was analyzed, it
was found that synthesis of readthrough mRNA at the SH/G
gene junction was increased approximately five-fold. How-
ever, this U4A combination had a less dramatic effect on the
SH/G junction than on the previously examined M/SH junc-
tion, perhaps due to the A at position 1, which has been
shown to enhance termination at the SH gene end (Harmon
and Wertz, 2002). It is possible that this A can partially
compensate for detrimental variations elsewhere in the gene
end, allowing higher levels of termination to occur at sub-
optimal gene end sequences.
The changes found in the U-tract lengths reported here
may have been caused by polymerase slippage similar to
that which occurs during polyadenylation of mRNAs (Barr
and Wertz, 2001). Previous work has shown that the HRSV
polymerase generates variant G proteins that are resistant to
monoclonal antibody neutralization by inserting and delet-
ing adenosine residues within short A runs in the G gene,
resulting in frameshift mutations (Garcia-Barreno et al.,
1990; Melero et al., 1997; Sullender et al., 1991). This may
occur by a similar slippage mechanism or by a mechanism
that may have some features in common with the RNA
editing mechanism, “stuttering,” as has been described for
the P genes of the paramyxoviruses Human parainfluenza
virus-3 and Sendai virus (Hausmann et al., 1999; Jacques et
al., 1994). Although the paramyxovirus editing sites previ-
ously described are within coding regions, it may be that a
similar mechanism may result in alteration to the length of
the U-tracts at HRSV gene ends. These may be selected for
if the altered termination efficiencies and the effect on
expression of downstream genes is advantageous.
The G gene end sequences of 75 isolates were available
in GenBank, and we analyzed these in addition to the 14
isolates described above. The majority of these isolates
contained two variations, an A-to-G change at position 4 in
the conserved sequence element 3 . . .UCAAU. . . 5 (A4G,
found in 68 isolates) and the deletion of the first nucleotide
in the nonconserved central region (-6G, found in 78 iso-
lates). Previous work had shown that position 4 in the
conserved 3 . . .UCAAU. . . 5 was extremely sensitive to
alteration (Cartee et al., 2003; Harmon et al., 2001). We
tested the effect of these variations on transcription and
found that termination was decreased and correspondingly
increased amounts of dicistronic readthrough RNAs were
produced in subgenomic replicons containing certain altered
G gene end sequences (Fig. 3B). Also, as would be expected
due to the obligatorily sequential nature of HRSV transcrip-
tion, the synthesis of the downstream monocistronic mRNA
species was also decreased in these replicons. The effect on
termination correlated with the A4G variation, rather than
the -6G variation. Isolates from the lineage bearing the A4G
variant G gene end sequence were found to express less F
protein than viruses with A2-like G gene end signals. At this
point we cannot exclude the possibility that other sequence
variations in these isolates could be contributing to this
phenotype.
Previous work had shown that when certain double mu-
tations were present in a gene end sequence, their effect on
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termination was additive (Harmon et al., 2001; Harmon and
Wertz, 2002). However, when the A4G and -6G variations
were both placed into the G gene end sequence, termination
efficiency was increased, although not to the level seen with
the A2 sequence. A similar compensatory phenotype was
observed at the NS2/N gene junction (Cartee et al., 2003).
To our knowledge, this is the first analysis of naturally
occurring variation in HRSV gene end sequences that af-
fects transcriptional termination and downstream mRNA
synthesis. It has been demonstrated for other nonsegmented
negative-strand viruses, however, that sequence changes in
gene junctions and noncoding regions can significantly alter
termination efficiency and thus downstream gene expres-
sion (Ayata et al., 2002; Bousse et al., 2002; Cattaneo et al.,
1986, 1987; Parks et al., 2001a, 2001b; Rassa and Parks,
1998, 1999; Wertz et al., 2002). In SV-5, termination is
inefficient at the M/F gene junction, apparently due to the
intergenic region sequence (Parks et al., 2001b; Rassa and
Parks, 1998, 1999). Changes in the SV-5 M/F intergenic
region sequence altered the termination efficiency at the M
gene end, resulting in changes in expression of the down-
stream genes (Parks et al., 2001b). Inefficient termination at
the Human parainfluenza virus-1 M/F gene junction corre-
lates with the sequence of the intergenic region, as well as
the F gene start and 3 noncoding region sequences (Bousse
et al., 2002). Measles virus strains have been isolated from
patients with subacute sclerosing panencephalitis that pro-
duce nearly undetectable levels of M protein due to high
levels of P-M dicistronic readthrough products, some of
which are associated with changes in the P gene end se-
quence (Ayata et al., 2002; Cattaneo et al., 1986, 1987)
Vesicular stomatitis Indiana virus (VSIV) can select for
mutations in its conserved gene end sequence that abrogate
termination within two passages (Wertz et al., 2002). This
selection decreases expression of an inserted foreign gene
that is detrimental, either by virtue of its position in the
genome introducing an additional attenuation step (Wertz
et al., 2002) or by some aspect of the gene product (Qui-
nones-Kochs et al., 2001). Our results present another ex-
ample of variation in transcriptional termination signals
regulating gene expression in nonsegmented negative-
strand viruses.
The only gene end sequences at which no changes were
found were the NS2 and M2 genes. It is possible that any
variation in a gene end sequence can alter termination and
that these gene end sequences have been optimized by the
virus to direct termination at certain efficiencies, such that
even a slight change is detrimental. The genes immediately
downstream of these gene end sequences are N and L,
respectively, and their gene products are critical to HRSV
replication. The N protein is required at levels high enough
to encapsidate the viral replication products (Collins et al.,
2001); therefore, decreased expression would be expected
to decrease the amount of viral replication. While the L
protein is required for replication and transcription of the
viral genome, it has been shown for VSIV that high levels
of polymerase can inhibit viral replication and growth
(Meier et al., 1987). However, work with Rabies virus has
shown that increasing L protein expression increased viral
CPE in cell culture and virulence in mice (Finke et al.,
2000). The authors postulated that highly pathogenic vi-
ruses could be detrimental to viral spread in the wild if they
killed their current host prior to transmission to a new host.
It would be interesting to examine a recombinant HRSV to
determine if slight changes to the termination efficiencies at
the NS2 and M2 gene ends alter growth of the virus, either
in cell culture or in animals.
A unique aspect of the data presented here is the obser-
vation that HRSVs containing the two main variant G gene
end sequences are segregated into two discrete phylogenetic
lineages. It has been shown that antibodies against either the
G or the F proteins can neutralize HRSV infectivity (Ander-
son et al., 1988). While the high variability of the G protein
(Cane et al., 1991, 1993, 1994; Cane and Pringle, 1991,
1995; Choi and Lee, 2000; Coggins et al., 1998; Collins et
al., 2001; Garcia et al., 1994; Garcia-Barreno et al., 1990;
Melero et al., 1997; Peret et al., 2000; Sullender, 2000;
Sullender et al., 1991; Waris, 1991) helps it to evade im-
mune system detection, extensive variation in the F protein
has not been observed, most likely due to the structural
constraints on fusion proteins which may make it difficult
for variation in antigenic character to occur while maintain-
ing a functional structure (Lopez et al., 1993). Previous
work involving rearrangement of the order of the VSIV G
gene has shown that relatively small changes in the level of
G protein expressed can have significant effects on the level
and rapidity of onset of the immune response (Flanagan et
al., 2000). Our results raise the intriguing possibility that,
rather than significantly varying the amino acid composition
of the F protein, certain genotypes of HRSV may decrease
F protein expression as a means of partially evading im-
mune system detection.
In conclusion, we have shown that although the gene
start sequences of HRSV clinical isolates are conserved, the
gene end sequences are variable. Certain variations, partic-
ularly the A4G variation at the end of the G gene, cause a
reduction in termination efficiency and expression of down-
stream monocistronic mRNA. This change in the G gene
end sequence is restricted to one subgroup A lineage and
may confer a selective advantage on viruses in this lineage.
These findings provide additional evidence that alteration of
termination efficiencies is a mechanism for modifying in-
dividual gene expression within the framework of a single
transcriptional promoter.
Materials and methods
Viruses and cells
HRSV clinical isolates were obtained from Children’s
Hospital of Alabama (Birmingham, AL, USA) and propa-
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gated in HEp-2 cells. Six subgroup A viruses, representing
the 1993–1994 (AL-180893, AL-180081), 1994–1995 (AL-
195131, AL-194465), and 1995–1996 (AL-203721, AL-
205342) epidemic seasons, were chosen for these studies
(Coggins et al., 1998; Sullender, 2000). Sequence analysis
was also performed on HRSV clinical isolates originally
collected in Birmingham (RSB89-1734, RSB89-6614,
RSB89-6190, RSB89-6256, RSB89-5857, RSB89-8106),
Glasgow (RSG1503), and Newcastle (RSS2), United King-
dom (Cane and Pringle, 1991, 1995; Tolley et al., 1996).
RT-PCR and nucleotide sequencing
HEp-2 cells were infected with 0.5 PFU per cell of virus
in minimal essential medium (MEM) supplemented with
2% heat-inactivated fetal bovine serum (FBS) at 37°C.
Total RNA was harvested from cell lysates using the
RNeasy mini kit (Qiagen) according to the manufacturer’s
instructions. RT-PCR was performed using a one-step RT-
PCR kit (Qiagen) with primers flanking each internal gene
junction (Hardy et al., 1999). The cDNA products were
purified by DNA extraction (Qiagen) following agarose gel
electrophoresis. Automated sequencing was performed by
fluorescent dye-termination on ABI model 377 and 373A
DNA sequencers (DNA Sequencing Facility, Center for
AIDS Research, UAB).
Plasmid construction
The plasmid pSH/G, encoding a dicistronic subgenomic
RNA replicon, was previously constructed from cDNA con-
taining nucleotides 4548 to 5226 from the prototype A2
strain of HRSV (Hardy et al., 1999). Plasmid pSH/G-4U,
which is identical to pSH/G except that the SH gene end has
a U-tract of four residues, was made by the QuikChange
method (Stratagene). The SH gene end sequence of this
plasmid was confirmed by automated sequencing.
The plasmid pG/F, encoding a dicistronic subgenomic
RNA replicon, was previously constructed from cDNA con-
taining nucleotides 5367 to 6013 from the prototype A2
strain of HRSV (Hardy et al., 1999). The G gene end
sequence of pG/F was altered by PCR using an upstream
mutagenic primer that annealed to the G/F gene junction
and the downstream primer FigG, which had a BglII site at
the 5 end. This product was used as the downstream primer
with the upstream primer GigF, which had an MfeI site at
the 5 end, in a second PCR reaction on pG/F. All PCR
products were synthesized with Pfu polymerase (Stratagene).
The final PCR product was digested with MfeI and BglII and
subcloned into these unique sites in pG/F to create plasmids
with the following G gene end sequences: 3-UCAGU-
GAAUUUUU-5 (pG/F-A4G), 3-UCAAUAAUUUUU-5
(pG/F-(-6G)), and 3-UCAGUAAUUUUU-5 (pG/F-A4G(-
6G)). These plasmids contain the following from 3 to 5 in
the negative sense: (1) the 44 nucleotide leader region; (2)
mRNA 1, the first 380 nucleotides of NS1 fused to the last
216 nucleotides of G; (3) the 52 nucleotide G/F intergenic
region; (4) mRNA 2, the first 357 nucleotides of F fused to
the last 67 nucleotides of L; and (5) the 154 nucleotide
trailer region.
Transfection and RNA analysis
HRSV RNA synthesis was analyzed in cells, essentially
as previously described (Cartee et al., 2003; Hardy et al.,
1999; Hardy and Wertz, 1998; Harmon et al., 2001; Harmon
and Wertz, 2002). Briefly, HEp-2 cells were grown in a
60-mm culture dish and infected with MVA-T7 at an m.o.i.
of 10 PFU per cell. MVA-T7 is a recombinant vaccinia
virus that expresses T7 RNA polymerase and was kindly
provided by B. Moss (Wyatt et al., 1995). Approximately
1 h after MVA-T7 infection, cells were transfected with
plasmids encoding a subgenomic replicon (4 g) and four
HRSV proteins — N protein (pN, 1.5 g), P protein (pP,
0.75 g), L protein (pPol1049N, 0.5 g) (Cartee et al., 2003),
and M2-1 protein (pM2-1, 0.3 g) — using 20 L Lipo-
fectin (Invitrogen). Transcription from these plasmids was
driven by T7 promoters.
Approximately 16 h posttransfection, the cells were ex-
posed to [3H]uridine (33 Ci/mL, Moravek Biochemicals)
in the presence of actinomycin D (10 g/mL) and cytosine
arabinoside (50 g/mL) for 6 h. RNA was purified from
cells using a phenol/chloroform/isoamyl alcohol extraction
method, as described previously (Cartee et al., 2003; Hardy
et al., 1999; Hardy and Wertz, 1998; Harmon et al., 2001).
3H-labeled RNAs were analyzed by 1.75% agarose/6 M
urea/25 mM citrate gel electrophoresis and detected by
fluorography.
RNA quantitation
The RNA species produced from the pSH/G and pG/F
replicons have been identified previously (Hardy et al.,
1999). These are the positive- and negative-sense replica-
tion products (rep.); the mRNA produced from the first gene
(mRNA1); the mRNA produced from the second gene
(mRNA2); and the readthrough product produced when the
HRSV polymerase fails to terminate at the end of the first
gene (r/t 1–2).
To determine the percentage readthrough at the SH or G
gene ends in the various replicons, RNA species that initiate
at the beginning of the first gene (mRNA1, r/t 1–2) were
quantitated by densitometry using a Howtek Scanmaster 3
and PDI Quantity One software, as recommended by the
manufacturer. Readthrough synthesis was calculated using
the following formula: % readthrough  100  [100 
mRNA1/(mRNA1  r/t 1–2)]. To obtain molar equivalents
of RNA, the optical density for each RNA species was
adjusted for the number of uridines incorporated into that
RNA and these molar amounts were used in calculating
percentage readthrough.
To quantitate mRNA2 synthesis by the variant pG/F
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replicons, mRNA2 levels were compared to the total levels
of mRNA. All RNA species were quantitated as described
above, and molar equivalents of RNA were used in all
subsequent calculations. Relative amounts of mRNA2 were
determined using the following formula: mRNA2 
mRNA2/(mRNA1  mRNA2  r/t 1–2), and these
amounts were compared to the amount of mRNA2 synthe-
sized by the A2 pG/F replicon.
35S-labeled protein analysis and quantitation
HEp-2 cells were infected with HRSV clinical isolates at
an m.o.i. of 0.5 as described above for RNA isolation for
RT-PCR. Approximately 16 h postinfection the media were
replaced with serum-free MEM that contained 5 g/mL
actinomycin D and incubated for 2 h; it was then replaced
with MEM lacking methionine and cysteine containing ac-
tinomycin D and incubated for an additional 30 min. Cells
were then exposed to [35S]methionine and [35S]cysteine
(10.5 Ci/mL, Trans 35S-label, ICN) in the presence of
actinomycin D for 3 h. Cells were lysed in 0.5 mL of cold
lysis buffer [1% NP-40, 0.4% sodium deoxycholate, 66 mM
EDTA, 10 mM Tris–HCl (pH 7.4)], followed by vortexing,
brief centrifugation to remove cell nuclei, and addition of 5
L of 10% sodium dodecyl sulfate. 35S-labeled proteins
were immunoprecipitated using monoclonal antisera recog-
nizing the HRSV F (MAb 19, a gift from Dr. Geraldine
Taylor) and N (Chemicon) proteins or using polyclonal
anti-HRSV antisera (Chemicon), added in excess, and pro-
tein G-Sepharose (Pharmacia Biotech), followed by separa-
tion by reducing SDS–PAGE on 11% polyacrylamide gels.
Labeled proteins were then visualized by fluorography and
quantitated using a STORM-860 PhosphorImager and Im-
ageQuant v1.2 software (Molecular Dynamics). The amount
of F protein expressed by each virus was determined rela-
tive to the amount of N protein or M protein expressed by
that virus and compared to the amount of F protein pro-
duced by A2.
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